HK1009978A1 - Recombinant adenovirus vaccines - Google Patents

Recombinant adenovirus vaccines

Info

Publication number
HK1009978A1
HK1009978A1 HK98110746A HK98110746A HK1009978A1 HK 1009978 A1 HK1009978 A1 HK 1009978A1 HK 98110746 A HK98110746 A HK 98110746A HK 98110746 A HK98110746 A HK 98110746A HK 1009978 A1 HK1009978 A1 HK 1009978A1
Authority
HK
Hong Kong
Prior art keywords
recombinant adenoviruses
antibodies
recombinant adenovirus
cell mediated
mediated immunity
Prior art date
Application number
HK98110746A
Other languages
English (en)
Inventor
Alan Robert Davis
Paul Porwen Hunt
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur Murthy
Shaw-Guang Lin Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1009978A1 publication Critical patent/HK1009978A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK98110746A 1992-08-07 1998-09-19 Recombinant adenovirus vaccines HK1009978A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92649192A 1992-08-07 1992-08-07

Publications (1)

Publication Number Publication Date
HK1009978A1 true HK1009978A1 (en) 1999-06-11

Family

ID=25453282

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110746A HK1009978A1 (en) 1992-08-07 1998-09-19 Recombinant adenovirus vaccines

Country Status (18)

Country Link
EP (1) EP0586076B1 (fr)
JP (1) JP4093597B2 (fr)
KR (1) KR100347219B1 (fr)
AT (1) ATE243755T1 (fr)
AU (2) AU680826B2 (fr)
BR (1) BR9303226A (fr)
CA (1) CA2101463C (fr)
DE (1) DE69333057T2 (fr)
DK (1) DK0586076T3 (fr)
ES (1) ES2201055T3 (fr)
FI (1) FI114318B (fr)
HK (1) HK1009978A1 (fr)
HU (2) HU214364B (fr)
IL (1) IL106508A (fr)
MX (1) MX9304765A (fr)
NZ (1) NZ248328A (fr)
PT (1) PT586076E (fr)
ZA (1) ZA935355B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196018T3 (es) * 1993-08-11 2003-12-16 Wyeth Corp Vacunas de adenovirus recombinantes.
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
JPH10512243A (ja) * 1994-12-30 1998-11-24 カイロン コーポレイション 遺伝子送達ビヒクルの非外傷性投与
KR100464395B1 (ko) * 1997-10-13 2005-02-28 삼성전자주식회사 반도체소자의비아홀형성방법
EP1200622A4 (fr) 1999-07-06 2004-12-22 Merck & Co Inc Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US8285390B2 (en) 2007-08-21 2012-10-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
EP2769703B1 (fr) 2009-04-30 2022-04-06 Zeltiq Aesthetics, Inc. Dispositif d'élimination de chaleur à partir de cellules riches en lipide sous-cutanées
BR112012018521A2 (pt) 2010-01-25 2019-09-24 Zeltiq Aesthetics Inc aplicadores para uso doméstico para remover de forma não invasiva calor de células subcutâneas ricas em lipídeos por meio de refrigerantes de mudança de fase, e dispositivos, sistemas e métodos associados
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US10722395B2 (en) 2011-01-25 2020-07-28 Zeltiq Aesthetics, Inc. Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells
WO2020028472A1 (fr) 2018-07-31 2020-02-06 Zeltiq Aesthetics, Inc. Procédés, dispositifs et systèmes pour l'amélioration d'une ou de plusieurs caractéristiques de la peau

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
AU9179891A (en) * 1990-12-19 1992-07-22 Epitope, Inc. Hiv reverse transcriptase vaccine
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes

Also Published As

Publication number Publication date
CA2101463A1 (fr) 1994-02-08
HU211691A9 (en) 1995-12-28
KR100347219B1 (ko) 2003-02-25
IL106508A0 (en) 1993-11-15
FI933495A0 (fi) 1993-08-06
FI933495A (fi) 1994-02-08
DE69333057T2 (de) 2004-07-08
PT586076E (pt) 2003-11-28
EP0586076A3 (fr) 1994-04-20
IL106508A (en) 1998-02-22
CA2101463C (fr) 2007-03-13
EP0586076A2 (fr) 1994-03-09
DK0586076T3 (da) 2003-10-20
DE69333057D1 (de) 2003-07-31
MX9304765A (es) 1995-01-31
EP0586076B1 (fr) 2003-06-25
KR940003566A (ko) 1994-03-12
FI114318B (fi) 2004-09-30
JPH06165689A (ja) 1994-06-14
ATE243755T1 (de) 2003-07-15
HU9302285D0 (en) 1993-11-29
ES2201055T3 (es) 2004-03-16
NZ248328A (en) 1997-05-26
HUT67302A (en) 1995-03-28
BR9303226A (pt) 1994-03-08
ZA935355B (en) 1995-01-23
AU715190B2 (en) 2000-01-20
AU3422797A (en) 1997-11-20
HU214364B (hu) 1998-03-30
AU680826B2 (en) 1997-08-14
AU4446593A (en) 1994-02-10
JP4093597B2 (ja) 2008-06-04

Similar Documents

Publication Publication Date Title
HK1009978A1 (en) Recombinant adenovirus vaccines
AU576907B2 (en) Oral vaccines comprising live recombinant adenoviruses
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
HK1009934A1 (en) Recombinant adenovirus vaccines
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090723